Dongyuan Zhu

机构：Shenyang University of Technology, Shandong Tumor Hospital, Shandong First Medical University, Genesee Community College · ORCID：0009-0000-5021-5964

发表论文 40 篇 · 总被引 339 次 · h-index 9

代表论文

• First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors (2023 · Journal of Hematology & Oncology · 被引 59)
• An optimization strategy for intra-park integration trading considering energy storage and carbon emission constraints (2024 · Journal of Cleaner Production · 被引 11)
• Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation (2023 · The Oncologist · 被引 7)
• Systemic bevacizumab for pediatric patients with aggressive recurrent respiratory papillomatosis: One single‐center experience of eight patients (2023 · Laryngoscope Investigative Otolaryngology · 被引 7)
• First report of efficacy and safety results from a phase 2 trial evaluating BNT327/PM8002 plus chemotherapy (chemo) as first-line treatment (1L) in unresectable malignant mesothelioma. (2025 · Journal of Clinical Oncology · 被引 5)
• First-line Anlotinib plus Anthracyclines and Ifosfamide Followed by Anlotinib Maintenance in Advanced Soft-Tissue Sarcoma: A Phase II Single-Arm Trial (2025 · Clinical Cancer Research · 被引 3)